| CARDIFF ONCOLOGY |
| USA |
| Gesundheit |
| US14147L1089 / A2P4GU |
| XE7C (Frankfurt) / CRDF (NASDAQ) |
| FRA:XE7C, ETR:XE7C, XE7C:GR, NASDAQ:CRDF |
| - |
| https://cardiffoncology.c.. |
|
Cardiff Oncology Inc. is a clinical-stage biotechnology company focused on developing novel therapies through PLK1 inhibition for cancers with significant unmet needs. Its lead candidate, onvansertib,..
>Volltext.. |
| 110.62 Mio. EUR |
| 61.73 Mio. EUR |
| 0.51 Mio. EUR |
| -41.36 Mio. EUR |
| -39.46 Mio. EUR |
| -0.59 EUR |
| 0.72 Mio. EUR |
| 15.04 Mio. EUR |
| -32.64 Mio. EUR |
| 3.56 |
| -23.59% |
| 11.04% |
| - |
| - |
| - |
| - |
| CARDIFF ONCOLOGY |
| 10.03.26 |
|